Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Haematologica - 1 Oct 2015

Springuel Lorraine, Renauld Jean-Christophe, Knoops Laurent

Abstract excerpt

Constitutive JAK-STAT pathway activation occurs in most myeloproliferative neoplasms as well as in a significant proportion of other hematologic malignancies, and is frequently a marker of poor prognosis. The underlying molecular alterations are heterogeneous as they include activating mutations in distinct components (cytokine receptor, JAK, STAT), overexpression (cytokine receptor, JAK) or rare JAK2 fusion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Hematologic Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematopoiesis

Share to Janus Kinases

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Share to STAT Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 26432382
DOI: 10.3324/haematol.2015.132142
PMCID: PMC4591756

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.PMID 26432382Read ↗

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of CancerSemantic proximity Read ↗

JAK-STAT pathway in hematological malignancies: achievements, challenges and future perspectivesSemantic proximity Read ↗

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumoursSemantic proximity Read ↗

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.Semantic proximity Read ↗

JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted TherapiesSemantic proximity Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK/STAT in leukemia: a clinical updateSemantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

Janus Kinases in LeukemiaSemantic proximity Read ↗

JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.Semantic proximity Read ↗

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.Semantic proximity Read ↗

Malignant JAK-signaling: at the interface of inflammation and malignant transformationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.